ArticleThe Journal of clinical investigation2022

IgE-neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE downregulation and relieves urticaria symptoms.

Be-Sheng Kuo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.